ReviewJournal of psychiatry & neuroscience : JPN2003
Interactions between the cytochrome P450 system and the second-generation antipsychotics.
Review in Journal of psychiatry & neuroscience : JPN, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports-A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.Expert opinion on pharmacotherapy · 2020Pooled it
- Toxicity of psychotropic drugs in patients with COVID-19: A systematic review.General hospital psychiatryPooled it
- Risperidone plasma levels, clinical response and side-effects.European archives of psychiatry and clinical neuroscience · 2005Trial
- Polypharmacy and Drug-Drug Interactions in Chronic Obstructive Pulmonary Disease: A Narrative Clinical Review.Pharmaceutics · 2026Review
- Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems.Drug safety · 2026Article
- Comparative analysis of sex-based, vendor-based, and species differences in cytochrome P450 metabolism.Scientific reports · 2026Article
- Longitudinal trends in blood concentrations of clozapine and norclozapine, inflammatory markers, and clinical outcomes in Japanese patients: a 12-week prospective study.Frontiers in psychiatry · 2026Article
- Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors.Frontiers in psychiatry · 2026Article
- Article
- Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans.International journal of molecular sciences · 2025Review
- Reactivity of Olanzapine and Tricyclic Antidepressants on the Protective Effects of Trolox on Lipid Peroxidation Evaluated Using Fluorescence Anisotropy, Electron Paramagnetic Resonance Spectrometry, and Thermal Analysis.ACS chemical neuroscience · 2025Article
- Olanzapine use for the treatment of adolescents with anorexia nervosa - reflecting on research and clinical practice.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2024Article
- Review
- Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.Clinical drug investigation · 2024Review
- Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.Journal of psychopharmacology (Oxford, England) · 2024Article
- Alert prescribing of clozapine: a comparison of five drug-drug interaction sources.Therapeutic advances in drug safety · 2024Article
- Rifampin - Risperidone and Divalproex Drug-drug Interaction: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Seventy Years of Antipsychotic Development: A Critical Review.Biomedicines · 2023Review
- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders.Advances in neurobiology · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYP1A2, with additional contributions by CYP2C19, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.
Indexed as
Identifiers
12670127PMC161731W1528478735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.